知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.026 seconds)

    Insulin Management
    2.
    发明申请
    Insulin Management 有权
    胰岛素管理

    公开(公告)号：US20170007761A1

    公开(公告)日：2017-01-12

    申请号：US15272972

    申请日：2016-09-22

    Applicant: Aseko, Inc.

    Inventor： Robert C Booth ,  Harry Hebblewhite

    IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145

    CPC classification number: G06F19/3468 ,  A61B5/14532 ,  A61B5/4839 ,  A61B5/7275 ,  A61M5/1723 ,  A61M2005/14296 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3561 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  G06F19/00 ,  G16H10/00 ,  G16H20/17 ,  G16H40/63

    Abstract: A method of managing insulin includes receiving blood glucose measurements on a computing device from a glucometer. The blood glucose measurements are separated by a time interval. The method includes determining, using the computing device, an insulin dose rate based on the blood glucose measurements and determining a blood glucose drop rate based on the blood glucose measurements and the time interval. The method also includes determining a blood glucose percentage drop based on the blood glucose measurements. The method includes decreasing the time interval between blood glucose measurements by the glucometer when the blood glucose drop rate is greater than a threshold drop rate, and decreasing the time interval between blood glucose measurements by the glucometer when the blood glucose percentage drop is greater than a threshold percentage drop.

    Abstract translation: 管理胰岛素的方法包括从血糖仪在计算装置上接收血糖测量值。 血糖测量值以时间间隔分开。 该方法包括基于血糖测量确定使用计算设备的胰岛素剂量率，并基于血糖测量值和时间间隔确定血糖降低率。 该方法还包括基于血糖测量来确定血糖百分比降低。 该方法包括：当血葡萄糖滴下率大于阈值下降率时，降低由血糖计进行的血糖测量之间的时间间隔，并且当血葡萄糖百分比下降大于a时，降低葡萄糖计测定血糖值之间的时间间隔 门槛百分比下降。

    Diabetes Management Therapy Advisor
    3.
    发明公开
    Diabetes Management Therapy Advisor 审中-公开

    公开(公告)号：US20230187083A1

    公开(公告)日：2023-06-15

    申请号：US18165306

    申请日：2023-02-06

    Applicant: Aseko. Inc.

    Inventor： Robert C Booth ,  Harry Hebblewhite

    IPC: G16H70/20 ,  G16H50/20 ,  G16H10/60 ,  G16H20/10 ,  G16H20/17 ,  G16H50/00

    CPC classification number: G16H70/20 ,  G16H50/20 ,  G16H10/60 ,  G16H20/10 ,  G16H20/17 ,  G16H50/00

    Abstract: A method includes obtaining training data for a plurality of patients of a patient population. The training data includes training blood glucose history data including treatment doses of insulin administered by the patients of the patient population and one or more outcome attributes associated with each treatment dose. The method also includes identifying, for each patient of the patient population, one or more optimum treatment doses of insulin from the treatment doses yielding favorable outcome attributes. The method also includes receiving patient-state information for the treated patient, determining a next recommended treatment dose of insulin for the treated patient based on one or more of the identified optimum treatment doses associated with the patients of the patient population having training patient-state information similar to the patient-state information for the treated patient, and transmitting the next recommended treatment dose to a portable device associated with the treated patient.

    Advising Diabetes Treatments
    5.
    发明公开
    Advising Diabetes Treatments 审中-公开

    公开(公告)号：US20230290475A1

    公开(公告)日：2023-09-14

    申请号：US18182249

    申请日：2023-03-10

    Applicant: Aseko, Inc.

    Inventor： Robert C Booth ,  John G. Clarke

    IPC: G16H20/17 ,  G16H50/30

    CPC classification number: G16H20/17 ,  G16H50/30

    Abstract: A method for managing glucose levels of a patient under the supervision of a healthcare professional (HCP). The method includes obtaining patient information for the patient, the patient information comprising patient medication data, patient monitoring data, and patient characteristic data. The method also includes creating a patient risk profile based on the patient information. The method also includes determining a likelihood that the patient will experience hyperglycemic effects based on the patient risk profile. The method also includes determining an optimum treatment plan for the patient based on the patient risk profile and the likelihood that the patient will experience hyperglycemic effects. The method also includes executing the optimum treatment plan.

    Insulin Management
    6.
    发明申请
    Insulin Management 审中-公开

    公开(公告)号：US20180366217A1

    公开(公告)日：2018-12-20

    申请号：US16109508

    申请日：2018-08-22

    Applicant: Aseko, Inc.

    Inventor： Robert C Booth ,  Harry Hebblewhite

    IPC: G16H20/60 ,  G16H40/67 ,  G16H10/40 ,  G16H80/00 ,  A61B5/145 ,  G16H20/17 ,  G06F19/00 ,  A61M5/14 ,  A61M5/172 ,  A61B5/00 ,  A61M5/142

    Abstract: A dosing controller for administering insulin. The dosing controller includes a data processing device and non-transitory memory in communication with the data processing device. The dosing controller receives blood glucose measurements of a patient from the glucometer, receives patient information, selects a subcutaneous insulin treatment from a collection of subcutaneous insulin treatments based on the blood glucose measurements and the patient information, and executes the selected subcutaneous insulin treatment. Each blood glucose measurement is separated by a time interval and includes a blood glucose time associated with a time of measuring the blood glucose measurement.

    Advising Diabetes Medications
    10.
    发明申请
    Advising Diabetes Medications 有权

    公开(公告)号：US20230139172A1

    公开(公告)日：2023-05-04

    申请号：US18089380

    申请日：2022-12-27

    Applicant: Aseko, Inc.

    Inventor： Robert C Booth ,  Andrew Rhinehart ,  Harry Hebblewhite

    IPC: G16H20/13 ,  G16H50/20 ,  G16H10/60 ,  G16H40/63 ,  G16H50/30 ,  G16H20/17

    Abstract: A method includes obtaining prescribing drug information and published guidelines for each of a plurality of ADMs available for managing glucose levels, and receiving patient information associated with a patient. The method also includes ordering total demerit values from lowest to highest, selecting a predetermined number of recommended ADMs associated with the lowest total demerit values, and determining a recommended dosage for each recommended ADM. The method also includes transmitting a therapy regimen to a patient device associated with the patient. The therapy regimen includes the recommended ADMs and the recommended dosage for each recommended ADM.

Patent Agency Ranking